Skye Bioscience Inc (SKYE) Stock Price, Quote & News

Company Profile

Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central ne...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 410 0266

Website: skyebioscience.com

Address:

11250 El Camino Real, Suite 100, San Diego, United States

Fellforit Sep. 17 at 3:31 AM

$SKYE buying opportunities abound.. PD for ceo of the year!!

0 · Reply

prismmarketview Sep. 16 at 9:46 PM

A heavy Wednesday: 7 of 27 PRISM indexes finished higher in a session where the selling was broad but shallow, with the damage concentrated in a handful of single names. Women's health (+5.29%), crypto mining (+1.56%) and healthcare (+1.19%) led the gainers, while oil and gas (-4.09%) and weight loss (-2.88%) lagged. Biggest single-stock moves: $PDSB $FEAM +39.68% led the gainers, while $SKYE -19.43%, $FBDT -17.00% and $PALI -16.13% led the decliners. Full board below. Index detail at http://prismmarketview.com

0 · Reply

Fellforit Sep. 14 at 7:11 PM

$SKYE where is everyone?

0 · Reply

prismmarketview Sep. 9 at 8:49 PM

A broad selloff Wednesday: 25 of 27 PRISM indexes closed lower, with global health (-4.52%), space (-4.16%) and EV (-3.71%) hit hardest. Only psychedelics (+2.80%) and oil & gas (+0.93%) finished green. Biggest single-stock moves: $IRD +32.03% and $SKYE +18.62% led the gainers, while $BBOT -23.76%, $WW -16.95% and $XPOF -16.04% led the decliners. Full board below. Index detail at http://prismmarketview.com

1 · Reply

tommy_john Sep. 9 at 7:27 PM

$SKYE yepper

0 · Reply

prismmarketview Sep. 9 at 4:11 PM

PRISM Mid-Day Movers: Pharmaceuticals and Biotech are Today's Leaders. Opus Genetics, Inc. (NASDAQ: $IRD ) surged, up 26.5% to $5.49 today, rebounding sharply from yesterday’s $4.34 close. Pulse Biosciences, Inc. (NASDAQ: $PLSE ) climbed 18.24% to $57.69 today, gaining $8.90 from its previous $48.79 close. Other Notable Movers: bioAffinity Tech ($BIAF ) up 14% Skye Bioscience ($SKYE ) up 10% Evommune, Inc. ($EVMN ) down -16% https://prismmarketview.com/prism-mid-day-movers-pharmaceuticals-and-biotech-are-todays-leaders/

0 · Reply

Fellforit Sep. 2 at 3:49 PM

$SKYE still around a quarter folks!

0 · Reply

Frab Sep. 1 at 6:29 PM

$SKYE LFG, move .

0 · Reply

shoh_jung_888 Sep. 1 at 1:07 PM

$SKYE Holding this garbage støck sınce øct 2ø2I. This is the biotech's version of the Titanic. Thx captain PD!

1 · Reply

tommy_john Sep. 1 at 3:33 AM

$SKYE 👀

0 · Reply

Skye Bioscience Proxy statement: Proxy filing

Aug 24, 2026, 8:00 AM EDT - 23 days ago

Skye Bioscience Proxy statement: Proxy filing

2026-08-21T23:50:13.000Z - 26 days ago

Skye Bioscience Inc trading halted, news pending

Aug 20, 2026, 8:00 AM EDT - 27 days ago

Skye Bioscience Proxy statement: Proxy filing

Aug 19, 2026, 8:00 AM EDT - 4 weeks ago

Skye Bioscience Proxy statement: Proxy filing

2026-08-16T13:19:03.000Z - 4 weeks ago

Skye Bioscience Inc trading halted, news pending

2026-08-16T13:09:41.000Z - 4 weeks ago

Skye Bioscience to acquire Redx Pharma via scheme of arrangement

2026-08-16T13:07:54.000Z - 4 weeks ago

Skye Bioscience Inc trading resumes

Aug 14, 2026, 4:00 PM EDT - 4 weeks ago

Skye Bioscience Quarterly report: Q2 2026

Aug 14, 2026, 10:00 AM EDT - 4 weeks ago

Skye Bioscience Transcript: M&A announcement

Aug 14, 2026, 10:00 AM EDT - 4 weeks ago

Skye Bioscience Press release: M&A announcement

Aug 14, 2026, 10:00 AM EDT - 4 weeks ago

Skye Bioscience Slides: M&A announcement

Aug 14, 2026, 9:33 AM EDT - 4 weeks ago

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Aug 14, 2026, 8:00 AM EDT - 4 weeks ago

Skye Bioscience Proxy statement: Proxy filing

May 26, 2026, 1:00 PM EDT - 3 months ago

Skye Bioscience Transcript: AGM 2026

May 20, 2026, 7:00 AM EDT - 3 months ago

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

May 12, 2026, 1:33 PM EDT - 4 months ago

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

2026-05-12T11:22:30.000Z - 4 months ago

Skye Bioscience price target lowered to $6 from $13 at Piper Sandler

2026-05-11T21:09:20.000Z - 4 months ago

Skye Bioscience reports Q1 EPS (32c), consensus (32c)

May 11, 2026, 4:01 PM EDT - 4 months ago

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 11, 2026, 4:00 PM EDT - 4 months ago

Skye Bioscience Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 4 months ago

Skye Bioscience Earnings release: Q1 2026

May 11, 2026, 7:00 AM EDT - 4 months ago

Skye Bioscience Slides: Corporate presentation

Apr 16, 2026, 8:00 AM EDT - 5 months ago

Skye Bioscience Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 5 months ago

Skye Bioscience Proxy statement: Proxy filing

Apr 7, 2026, 7:00 AM EDT - 5 months ago

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Apr 6, 2026, 8:00 AM EDT - 5 months ago

Skye Bioscience Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 5 months ago

Skye Bioscience Proxy statement: Proxy filing

Apr 3, 2026, 7:00 AM EDT - 5 months ago

Skye Bioscience Slides: Corporate presentation

Apr 2, 2026, 7:00 AM EDT - 5 months ago

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Mar 10, 2026, 4:30 PM EDT - 6 months ago

Skye Bioscience Earnings Call Transcript: Q4 2025

Mar 10, 2026, 4:30 PM EDT - 6 months ago

Skye Bioscience Earnings release: Q4 2025

Mar 10, 2026, 4:30 PM EDT - 6 months ago

Skye Bioscience Annual report: Q4 2025

Mar 10, 2026, 4:30 PM EDT - 6 months ago

Skye Bioscience Slides: Q4 2025

2026-03-10T20:12:08.000Z - 6 months ago

Skye Bioscience reports Q4 EPS (36c), consensus (31c)

Mar 10, 2026, 4:01 PM EDT - 6 months ago

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 5, 2026, 7:00 AM EST - 6 months ago

Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

Feb 21, 2026, 6:00 AM EST - 6 months ago

Skye Bioscience Slides: Corporate presentation

2026-02-02T12:26:39.000Z - 7 months ago

Skye Bioscience announces 52-week data from Phase 2a CBeyond study of nimacimab

Feb 2, 2026, 7:00 AM EST - 7 months ago

Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide

2026-01-29T12:20:16.000Z - 7 months ago

Skye Bioscience presents poster on efficacy of Nimacimab

Jan 29, 2026, 7:00 AM EST - 7 months ago

Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference

Jan 21, 2026, 7:00 AM EST - 7 months ago

Skye Bioscience to Present Poster at Keystone Obesity Conference

2026-01-12T12:12:34.000Z - 8 months ago

Skye Bioscience provides 2026 corporate outlook

Jan 12, 2026, 7:00 AM EST - 8 months ago

Skye Provides 2026 Corporate Outlook

2026-01-05T12:25:09.000Z - 8 months ago

Skye Bioscience, Halozyme enter collaboration, license agreement

HALO

2026-01-05T12:11:01.000Z - 8 months ago

Halozyme, Skye Bioscience announce global collaboration, license agreement

HALO

Jan 5, 2026, 7:00 AM EST - 8 months ago

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

HALO

Dec 19, 2025, 2:56 PM EST - 9 months ago

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

Dec 8, 2025, 7:11 AM EST - 9 months ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation

Dec 4, 2025, 11:30 AM EST - 9 months ago

Skye Bioscience Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 12:55 PM EST - 9 months ago

Skye Bioscience Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 24, 2025, 7:00 AM EST - 9 months ago

Skye Bioscience to Participate in Upcoming Investment Conferences

Nov 10, 2025, 4:30 PM EST - 10 months ago

Skye Bioscience Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 10 months ago

Skye Bioscience Earnings release: Q3 2025

Nov 10, 2025, 4:30 PM EST - 10 months ago

Skye Bioscience Quarterly report: Q3 2025

2025-11-10T21:16:34.000Z - 10 months ago

Skye Bioscience reports Q3 EPS (32c), consensus (32c)

Nov 10, 2025, 4:01 PM EST - 10 months ago

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

2025-11-05T12:52:20.000Z - 10 months ago

Skye Bioscience to present topline data from CBeyond on nimacimab

Nov 5, 2025, 7:05 AM EST - 10 months ago

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

Nov 5, 2025, 7:00 AM EST - 10 months ago

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

CNTX

Oct 6, 2025, 8:00 AM EDT - 11 months ago

Skye Bioscience Transcript: Study Update

Oct 6, 2025, 8:00 AM EDT - 11 months ago

Skye Bioscience Press release: Study Update

Oct 6, 2025, 8:00 AM EDT - 11 months ago

Skye Bioscience Slides: Study Update

Oct 6, 2025, 7:09 AM EDT - 11 months ago

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Oct 6, 2025, 7:00 AM EDT - 11 months ago

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Sep 19, 2025, 7:00 AM EDT - 12 months ago

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Sep 10, 2025, 7:00 AM EDT - 1 year ago

Skye Bioscience Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 7:00 AM EDT - 1 year ago

Skye Bioscience Slides: Corporate Presentation

Sep 4, 2025, 8:00 AM EDT - 1 year ago

Skye Bioscience Transcript: KOL Event

Sep 4, 2025, 7:00 AM EDT - 1 year ago

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Sep 2, 2025, 7:00 AM EDT - 1 year ago

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Aug 27, 2025, 7:00 AM EDT - 1 year ago

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Aug 21, 2025, 7:00 AM EDT - 1 year ago

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Skye Bioscience Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Skye Bioscience Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Skye Bioscience Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Skye Bioscience Slides: Q2 2025

Aug 7, 2025, 4:01 PM EDT - 1 year ago

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Jul 30, 2025, 7:00 AM EDT - 1 year ago

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Fellforit Sep. 17 at 3:31 AM

$SKYE buying opportunities abound.. PD for ceo of the year!!

0 · Reply

prismmarketview Sep. 16 at 9:46 PM

0 · Reply

Fellforit Sep. 14 at 7:11 PM

$SKYE where is everyone?

0 · Reply

prismmarketview Sep. 9 at 8:49 PM

1 · Reply

tommy_john Sep. 9 at 7:27 PM

$SKYE yepper

0 · Reply

prismmarketview Sep. 9 at 4:11 PM

0 · Reply

Fellforit Sep. 2 at 3:49 PM

$SKYE still around a quarter folks!

0 · Reply

Frab Sep. 1 at 6:29 PM

$SKYE LFG, move .

0 · Reply

shoh_jung_888 Sep. 1 at 1:07 PM

$SKYE Holding this garbage støck sınce øct 2ø2I. This is the biotech's version of the Titanic. Thx captain PD!

1 · Reply

tommy_john Sep. 1 at 3:33 AM

$SKYE 👀

0 · Reply

YazzJr Aug. 31 at 7:53 PM

$SKYE This stock is so far down that even if Dhillon can sell Nimicimab, it wont be for enough money to even get a fraction of what investors lost. He would need to sell Nimicimab for over $100M for most to break even. And let's face it, if they could have sold it for $100M they would have done that instead of this shite deal with they did with Redx. I think the most he can get will be between $5M to $10M. So if they sell it for $10M and shareholders get 90% of that, that would be about $2.15 a share that investors get. That is IF he can sell it. It's a two time loser already.

1 · Reply

Jangalang Aug. 31 at 12:39 PM

$SKYE … Scamming investors for the past 10 years.

0 · Reply

Blinddartthrowerl Aug. 29 at 4:38 PM

$SKYE If anyone is friends with $MISSIONARYPOSITION or whatever his name is could you please ask him why he blocked me?

3 · Reply

Blinddartthrowerl Aug. 29 at 2:47 AM

$SKYE What did i do?

0 · Reply

Frab Aug. 28 at 4:45 PM

$SKYE have a small position, averaging down a bit , holding a little while longer, see what happens.

0 · Reply

Jangalang Aug. 27 at 8:08 PM

$SKYE … This company has been scamming investors for 10+ years. I have been holding this for a decade. I have been dealt multiple reverse splits, and name changes. How do these criminal companies get away with this robbery?

1 · Reply

MGAP Aug. 26 at 7:17 PM

$SKYE yes in

1 · Reply

Polsky Aug. 26 at 5:19 PM

$SKYE @MissionaryTrader Adding? :D

0 · Reply

YazzJr Aug. 26 at 1:53 PM

$SKYE This stock is a hot mess. I thought it would take about a month before it went under $2, it hasn't even taken 3 days. Unfortunately by this time next month it will once again find itself out of compliance with the NASDAQ.

1 · Reply

lecorb Aug. 25 at 9:02 PM

$SKYE After R/S 08/24 DEFA14A https://app.quotemedia.com/data/downloadFiling?webmasterId=500&ref=320299230&type=HTML&symbol=SKYE&cdn=8e301247c946f54816de4107d1175849&companyName=Skye+Bioscience+Inc.&formType=DEFA14A&formDescription=Additional+proxy+soliciting+materials+-+definitive&dateFiled=2026-08-24&_gl=1*cd1x3p*_gcl_au*MTc3NDc0NDYuMTc4NzU0NjAyMA..

0 · Reply

Frab Aug. 25 at 8:30 PM

$SKYE

0 · Reply

MissionaryTrader Aug. 24 at 11:11 PM

$SKYE I still think the odds are relatively high that an agreement for Nimacimab will be reached and announced in the near term. It appears that is the only way they’ll get enough investors to vote yes for the proxy and to avoid further dilution from the equity line prior to the merger.

2 · Reply

Market Cap	9.34M
Revenue (ttm)	0.00
Net Income (ttm)	-55.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	117,700
Avg Vol	94,661
Day's Range	N/A - N/A
Shares Out	4.43M
Stochastic %K	4%
Beta	2.90
Analysts	Sell
Price Target	$60.80